Methotrexate and Pralatrexate  by Wood, Gary S. & Wu, Jianqiang
Methotrexate and
Pralatrexate
Gary S. Wood, MD*, Jianqiang Wu, MD, PhDKEYWORDS
 Methotrexate  Pralatrexate  Dihydrofolate reductase  Folate  Folic acid  Purine synthesis
 S phase  Apoptosis
KEY POINTS
 Methotrexate (MTX) and pralatrexate (PDX) are competitive inhibitors of folate metabolism that
block dihydrofolate reductase, thereby preventing thymidylate and purine synthesis and resulting
in cell cycle arrest in the S phase.
 MTX and other folate inhibitors also reduce cellular levels of S-adenosylmethionine, the principal
methyl donor for methyltransferases, thereby inhibiting DNA methylation.
 In CTCL, this derepresses tumor suppressor genes such as the death receptor, Fas (CD95), thereby
enhancing apoptosis.
 These properties make folate antagonists useful for the treatment of lymphomas, either as single
agents or in combination with other therapies that enhance or complement their effects.INTRODUCTION
Methotrexate (MTX) is a well-known antimetabolite
that blocks the action of dihydrofolate reductase,
thereby inhibiting the metabolism of folic acid. It
has been used widely since the 1950s to treat a va-
riety of neoplastic and inflammatory diseases.
Recently, a more potent analog, pralatrexate
(PDX), has been developed and approved by the
Food and Drug Administration (FDA) for the treat-
ment of peripheral T-cell lymphomas (PTCLs).
This article discusses some emerging concepts
relevant to the optimal use of folate antagonists
and reviews these drugs in regard to the therapy
for cutaneousT-cell lymphomas (CTCLs), including
clinical indications, mechanism of action, pharma-
cokinetics, dosing regimens, response rates, and
adverse effects. According to convention, MTX
will be used as the abbreviation for methotrexate.
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EMERGING CONCEPTS RELEVANT TO THE
OPTIMAL USE OF FOLATE ANTAGONISTS
The Role of Folate Antagonists in the
Epigenetic Regulation of Gene Expression
The products of at least 5 tumor suppressor genes
generally known to be silenced by promoter
methylation have been reported to be deficient in
mycosis fungoides (MF) and Se´zary syndrome
(SS), FAS/CD95, FAS-ligand, p16, p21, and pro-
tein phosphatase 4 regulatory subunit-1
(PP4R1).2–11 These and other genes are also
known to be silenced by promoter methylation in
many other cancers (eg, TRAIL-R1, TRAIL-R2,
p16, p21, hMLH1, MGMT, and RASSF1A).12,13
These findings suggest that demethylating agentsaboratory Research & Development Service of the VA
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Wood & Wu748could benefit MF/SS patients by derepressing
silenced tumor suppressor genes. Although FDA-
approved for use in other diseases, traditional de-
methylating agents such as 5-azacytidine and
decitabine have a toxicity profile that discourages
their use for the treatment of chronic cutaneous
lymphomas such as MF/SS. One of the most
exciting aspects of folate antagonists is the recent
realization that, in addition to their well-established
role as S phase cell cycle inhibitors, they can also
act as DNA methylation inhibitors.2,14 Most of the
relevant experiments have been performed using
MTX; however, all related folate antagonists
should share the same basic properties (see later
discussion).The Importance of Combination Therapy for
Cancer
Inhibition of DNA methylation constitutes a novel
mechanism of action and rationale for the use of
MTX and related compounds in the management
of cutaneous lymphomas. It also provides a new
justification for their use in combination with other
treatments that produce effects complementary to
those of folate antagonists. The advantages of
combination therapy relative to monotherapy for
cancer treatment have been calculated recently
by Bozic and colleagues.15 In brief, they used
mathematical modeling to show that by the time
a tumor reaches a few millimeters in diameter it
is likely to harbor hundreds to thousands of mutant
cells that are resistant to any particular monother-
apy. This typically results in short-term clinical
benefit followed by treatment failure because
resistant mutant tumor clones proliferate in
response to the selection pressures of monother-
apy. In contrast, dual therapy results in long-term
disease control in most cases, if there are no mu-
tations in a single cell that cause cross-resistance
to both agents. The chances of cross-resistance
are diminished if the 2 agents target different path-
ways. For patients with large disease burden in
which the number of resistant mutants is greater,
triple therapy is needed. The mathematical models
also showed that simultaneous therapy with 2
agents is much more effective than when they
are used as sequential therapies.
The implications of these mathematical models
are relevant to folate antagonists because these
drugs can be used in combination with other treat-
ments that have different mechanisms of action
and affect multiple cellular pathways. Table 1
summarizes examples of MTX in combination
with other modalities. Using this combination ther-
apy approach, the likelihood of a favorable thera-
peutic outcome can be enhanced.TREATMENT
Indications
MTX and PDX have been used to treat a wide vari-
ety of cancers. Among the cutaneous lymphomas,
MTX has been used primarily to treat MF/SS and
primary cutaneous CD301 lymphoproliferative
disorders (LPDs) such as lymphomatoid papulosis
(LyP) and anaplastic large cell lymphoma (cALCL).
PDX is FDA-approved for refractory or relapsed
PTCLs. Among the cutaneous lymphomas, it has
proven efficacy for advanced stages of MF/SS,
including MF with large cell transformation
(LCT).16,17 It has also been used to treat other rarer
forms of primary CTCLs.18–20 Folate antagonists
have not been used widely to treat cutaneous
B-cell lymphomas. In fact, MTX has been associ-
ated with the development of cutaneous B-cell
LPDs (sometimes related to Epstein-Barr virus),
many of which regress when MTX is reduced or
discontinued.21,22
Mechanism of Action
MTX and PDX are folic acid analogues that block
cell division in the S phase.23,24 They are competi-
tive inhibitors of dihydrofolate reductasewith an af-
finity for this enzyme that is several logsgreater than
that of its natural substrate, folate. Dihydrofolate
reductase converts dihydrofolate to tetrahydrofo-
late, which is required for synthesis of thymidylate
and purine nucleotides involved in DNA and RNA
synthesis. It also inhibits the folate-dependent en-
zymes of purine and thymidylate synthesis such
as glycinamide ribonucleotide transformylase,
aminoimido-caboxyamido-ribonucleotide transfor-
mylase, and thymidylate synthase. MTX also
inhibits methionine synthase, thereby reducing
S-adenosyl methionine (SAM) levels. Because
SAM is the principal methyl donor for DNA methyl-
transferases (DNMTs),25,26 the authors propose
that MTX can act as a demethylating agent by
depleting DNMTs of their SAM methyl donor sup-
ply. The mechanism underlying this effect is illus-
trated in Fig. 1. Recently, the authors reported
in vitro and ex vivo evidence that MTX acts as a de-
methylating agent for the promoter of the FAS/
CD95 death receptor by blocking the synthesis of
SAM.14 When CTCL cell lines and freshly isolated
leukemic CTCL cells were treated with MTX, it re-
sulted in decreased SAM levels, decreased FAS
promoter methylation, and increased FAS protein
expression. This enhanced FAS expression was
accompanied by a major increase in sensitivity to
FAS pathway apoptosis, especially for leukemic
cells. In strong support of the authors’ hypothesis
regarding MTX’s mechanism of action, experi-
ments using CTCL lines with high baseline FAS
Table 1
Novel combination therapies for cutaneous T-cell lymphomas involving methotrexate
Other Agent Rationale
Interferon In addition to effects promoting a TH1 immune response, IFN-a also upregulates
Fas (CD95) by a STAT-1–dependent mechanism that is distinct from the effects of
MTX on Fas. This combination is effective for advanced MF/SS; 74% complete
response rate at 1 year among subjects with advanced CTCL (stage IIB–IVB).34
HDAC There is well recognized interaction between DNMTs and HDACs, which
collaborate to silence tumor suppressor genes. HDAC inhibitors and
demethylating agents have shown synergistic reactivation of genes silenced by
methylation.49 Recent findings showed that the class III HDAC, SIRT1, is
overexpressed in CTCL and that its knock-down or inhibition induced growth
arrest and apoptosis.50 Combination therapy with vorinostat is effective for
controlling SS.
Photodynamic
therapy
Photodynamic therapy upregulates Fas-ligand. Combined with MTX, both Fas and
Fas-ligand are increased, resulting in greater apoptosis than with either agent
alone (ePDT).51
UV phototherapy Narrow-band UVB upregulates Fas-ligand. Combination therapy is effective in
treating generalized patch and plaque MF.
Ionizing radiation In addition to its direct cytotoxic effects associated with DNA and other cell
damage, local radiation therapy increases Fas-ligand. Combined with MTX, it is
postulated that both Fas and Fas-ligand are increased, resulting in greater
apoptosis. Combination therapy induces a durable complete local response in
follicular MF extensively involving both ears and external ear canals (associated
with an enhanced but transient inflammatory reaction to radiation therapy).
c-CBL inhibitor Agents that block c-CBL (an E3 ubiquitin ligase) upregulate Fas-ligand. When
combined with MTX, both Fas and Fas-ligand are increased resulting in extensive
apoptosis (still under investigation).52
Abbreviations: DNMT, DNA methyltransferase; ePDT, epigenetically enhanced photodynamic therapy; HDAC, histone de-
acetylase inhibitor; IFN-a, alpha-interferon; SIRT1, silent information regulator type-1; STAT, signal transducer and acti-
vator of transcription; TH1, type 1 helper T cell.
Methotrexate and Pralatrexate 749promoter methylation showed that the addition of
SAM reversed both the decreased FAS promoter
methylation and the increased FAS protein expres-
sion induced by MTX. Representative results are
shown in Figs. 2 and 3, respectively. In aggregate,
these in vitro and ex vivo data consistently support
not only our hypothesis but also its clinical rele-
vance. Other folate antagonists that we have tested
(eg, pemetrexed) showed similar results. Therefore,
we expect the same will be true of PDX.
In addition to its effects onDNAmethylation,MTX
(and related compounds) likely inhibit protein
methylation because SAM is also the principal
methyl donor for protein methyltransferases. For
example, MTX was able to inhibit carboxyl
methylation of Ras (possibly by inhibiting isopre-
nylcysteine carboxylmethyltransferase), thereby
down-regulating Ras signaling, which is a major
inducer ofDNAmethylation inmanycancers.13,27,28
Like acetylation,methylationof histonesplays a key
role in gene regulation. MTX is likely to reduce the
activity of histone methyltransferases such as
SETDB1 and SUV39. Histone methylation at H3K9
and H3K27 is associated with gene silencing,whereas methylation at H3K4 is associated with
gene activation.12 There is a recent report that
MTX can inhibit the expression of methionine S-ad-
enosyltransferase-1 and -2 genes.29 This would
also reduce SAM levels by blocking the conversion
of methionine to SAM.Pharmacokinetics
Therapeutic levels ofMTX (1mM)are reachedat 1 to
5 hours after an oral dose of 20 mg/m2. Levels
remain greater than 0.1 mM for about 6 hours. Inhi-
bition of DNA synthesis ends at levels below
0.01 mM. Inhibition of protein synthesis ends at
levels below 0.1 mM.30 In the plasma, about 50%
to 70% of MTX is protein-bound (mainly to albu-
min). In the dose range generally used for cuta-
neous lymphomas, little MTX enters the central
nervous system.There is a triphasic disappearance
of MTX that depends on drug distribution, renal
clearance, and the enterohepatic circulation. The
mean terminal half-life is about 10 hours.
Relative to MTX, PDX has preferential uptake in
cells due to its increased affinity for the reduced
Fig. 1. MTX inhibits DNA methylation by depleting
SAM. Chain of methyl group (Me) transfer is shown
underlined from N-Me-tetrahydrofolate (Me-THF) to
Me-vitamin B12 to methionine (M) to SAM to
Me-DNA. MTX competitively inhibits dihydrofolate
reductase (DHFR) which is involved in the multistep
conversion of folate to Me-THF and inhibits methio-
nine synthase (MS) and subsequent downstream
methyl transfers that normally generate SAM. Other
factors shown: homocysteine (HC), methionine adeno-
syltransferase (MAT), S-adenosylhomocysteine (SAH),
SAH hydrolase (SAHH). The upper portion of the dia-
gram is simplified and does not show that the
immediate product of DHFR is THF, which is then con-
verted into methylene THF before generation of Me-
THF, which is then converted back to THF. Methylene
THF is the more proximate precursor of deoxythymi-
dine monophosphate (dTMP) and purines. DNMT,
DNA methyltransferase.
Wood & Wu750folate carrier type 1 (RFC-1). This may give PDX
greater selectivity for cancer cells because many
tumors overexpress RFC-1. At an intravenous (IV)
PDX dose of 150 mg/m2 biweekly, the mean area
under the curve (AUC) was 20.6 mM times hours,
and themean terminal half-life was 8 hours.1 Expo-
sure to IV PDX (AUC) is controlled with dosing
based on body size. Pretreatment with folic acid
and vitamin B12 can diminish the incidence and
severity ofmucositiswhile retainingdrug efficacy.31
MTX and PDX are metabolized intracellularly
into polyglutamates by folylpolyglutamyl synthe-
tase.16,32 These polyglutamates are preferentially
retained in cells, thereby making them less sus-
ceptible to efflux-based drug resistance. The
extent of polyglutamylation depends on both
drug concentration and the duration of drug expo-
sure. This process may be enhanced for PDX. Pol-
yglutamylation is often upregulated in cancer cells,providing another potential form of relative selec-
tivity for PDX.
Most of an MTX dose is excreted unchanged in
the urine within 24 hours. A minority is metabolized
during enterohepatic circulation. There are many
genes that can affect the processing of folate an-
tagonists, including RFC-1 (influx), ABCC1 and
ABCG2 (efflux), adenosine receptors 1 and 2, and
folate polyglutamates. For example, a single nucle-
otide polymorphism in exon 28 of the ABBC1 gene
alters cellular efflux of MTX and affects its effi-
cacy.33 In addition to these variables, younger
age correlates with enhanced distribution and
elimination of these agents.
Typical Dosing
For CTCLs, MTX is usually administered orally
once weekly at a dose of 10 to 25 mg, although
higher doses have been used. The total dose is
often divided into 2 or 3 portions taken 12 hours
apart to enhance drug absorption and decrease
gastrointestinal (GI) side effects.30 Higher doses
of MTX are sometimes used (for example,
10 mg/m2 biweekly in combination with alpha-
interferon [IFN-a]).34 LyP is often quite sensitive to
MTX and sometimes responds well to weekly
doses as low as 5mg. Oral folic acid supplementa-
tion (1–5 mg daily) ameliorates GI symptoms35;
however, the dose or dosing of folic acid might
affect efficacy.36 When high-dose MTX (60–
240 mg/m2 IV) has been used to treat advanced
MF/SS, it has been accompanied by leucovorin (fo-
linic acid) rescue tominimize damage to normal tis-
sues and to counteract acute toxicity.37 Currently,
such high-dose IV regimens are rarely used for
cutaneous lymphomas.
Although higher and lower doses have been
used successfully for various CTCLs, PDX is usu-
ally administered IV at 15 mg/m2/wk for 3 weeks
out of every 4 week cycle.16 The total number of
cycles depends on clinical response and toxicity.
In addition to daily folic acid supplementation
(1 mg orally), patients receive vitamin B12 supple-
mentation (1 mg intramuscular [IM] every 8–
10 weeks).
Response to Therapy
Methotrexate
Despite its longstanding and fairly common use in
the management of MF/SS patients, relatively few
clinical studies of MTX have been published. The
response of MF/SS subjects to low-dose MTX
(defined commonly as <100 mg/wk but often
limited to doses30mg/wk that donot require folic
acid to prevent toxicity) ranges from “definite
improvement” in 9 out of 16 (using 2.5–10 mg/d)38
Fig. 2. MTX reduces FAS promoter methylation. SAM reverses it. Demethylation of 6 CpG sites in the FAS pro-
moter was detected by pyrosequencing after treatment with MTX in Fas promoter methylation-high CTCL cell
lines (SZ4, HH). The y-axis shows the percentage of the methylation. The upper lines are the dimethyl sulfoxide
(DMSO) controls. The lower lines show the demethylating effect of MTX. The middle lines show that exogenous
SAM can reverse the demethylating effect of MTX.
Methotrexate and Pralatrexate 751to an overall response (complete response [CR]
plus partial response [PR]) in 17out of 29with eryth-
rodermic MF (E-MF) and 20 out of 60 with plaque
MF (using a median dose of 25 mg/wk).39,40
Although rarely used currently, MF/SS subjects
treated with high-dose MTX (up to 240 mg/m2 IV)
showed 9 out of 11 with greater than 80% clearing
including 7 of these with CR.37 An overall responserate to MTX monotherapy in SS is difficult to esti-
mate because of the small number of cases re-
ported. There is one published phase I-II study of
subjects with stage IA or IB MF treated topically
with 1% MTX compounded in a hydrophilic gel
containing laurocapram to enhance percutaneous
absorption. After every-other-day application for
24 weeks, 7 out of 9 subjects showed “slight
Fig. 3. MTX increases FAS death receptor protein expression; SAM reverses it. CTCL cell lines (HH, SZ4) show
increased expression of FAS after treatment with MTX. Addition of exogenous SAM almost fully reverses this
FAS upregulation. FAS protein detected by flow cytometry. Y-axis: fold change in mean fluorescence intensity.
Asterisks represent statistically significant t test differences between the MTX samples and the no-treatment con-
trols or the MTX 1 SAM samples (2-tailed P<.05 was considered statistically significant).
Wood & Wu752to moderate improvement” with statistically signif-
icant reductions in induration and pruritus without
any significant toxicity.41
There are also studies usingMTX in combination
with other therapies for MF/SS. The largest in-
volves 158 subjects with stage IIB to IVA MF/SS
treated with MTX (10 mg/m2 twice a week) plus
IFN-a-2a (9 MU 3 times a week) for 6 months.34
Those with PR continued for another 6 months
on IFN and MTX and those with CR at 6 or
12 months continued only on IFN. At 6 months,
there was 49% CR and at 12 months, the CR
was 74%. The 10-year estimated survival was
69%. Toxicity was mild despite that there was no
folic acid supplementation. The impressive clinical
efficacy observed in this study is supported by the
authors’ own in vitro and ex vivo data that demon-
strated greater MF/SS tumor cell killing with the
combination of MTX and IFN-a than with either
agent alone.34 A small study of IV MTX 60 mg/m2
IV followed by 5-fluorouracil 20 mg/kg with leuco-
vorin rescue showed at least 80% clearing in 2 out
of 2 SS subjects and 1 out of 2 E-MF subjects.42 A
single SS subject had a durable (>4 year) PR
following combination therapy with MTX
(10 mg/wk) and etoposide (25 mg/d).43
Low-dose MTX (5–25 mg/wk) is recommended
by expert consensus for the treatment of primary
cutaneous CD301 LPDs, including LyP, cALCL,and intergrades. Many subjects treated with MTX
for LyP have been reported in the literature; how-
ever, there is a paucity of published data regarding
its overall efficacy for cALCL.44 In the largest study
of low-dose MTX for primary cutaneous
CD301 LPDs, there was an overall response rate
of 87% among 45 subjects (mostly LyP).45 A me-
dian dose of 20 mg/wk was given for 1 year fol-
lowed by maintenance therapy typically at 2 wk
intervals. After treatment was discontinued, about
one-quarter of the responders remained disease-
free for at least 2 years. From the aggregate
data, it is clear that low-dose MTX is effective for
controlling LyP in most cases; however, relapse
off therapy is common. If the extent of relapse is
clinically significant, maintenance therapy may
be needed for an extended period. There is a
case report of LyP responding to local application
of topical MTX.46
Pralatrexate Regarding treatment of advanced
MF/SSwithPDX, there is adosedeescalating study
in which the starting dose was 30 mg/m2/wk IV for
3 weeks out of every 4-week cycle.16 The dose
was progressively reduced to find the optimal bal-
ancebetweenefficacyand toxicity.Overall, 54 sub-
jects were treated, 29 with the optimized schedule
of 15mg/m2/wk IV for 3 of 4 weeks (median of 4 cy-
cles). The overall response among these 29 cases
Methotrexate and Pralatrexate 753was 45%,mostly PRs with 2 CRs. Another study of
subjects with relapsed or refractory PTCLs
included 12 subjects with MF and LCT.20 The over-
all response rate was 58% by investigator assess-
ment and 25% by central review.
PDX therapy for cALCL or other rare types of
CTCL is not well reported. However, a few cases
are contained in larger studies of PTCLs and
showed some objective responses, including
CRs.16,18–20 In addition, 17 subjects with the sys-
temic CD301 cALCL showed an overall response
of rate of 35%.20
Trimetrexate Finally, there is a study of trimetrex-
ate (another MTX-related folate antagonist) admin-
istered IV at a dose of 200 mg/m2 biweekly. There
was a 47% overall response rate among 15MF/SS
cases (most with LCT).47
Adverse Effects
MTX side effects include GI (nausea, vomiting, sto-
matitis, ulcers, diarrhea), bonemarrow (leukopenia,
anemia, thrombocytopenia), liver (increased trans-
aminases, hepatitis, fibrosis, cirrhosis; the latter 2
related to cumulative dose), lung (pneumonitis,
fibrosis), pregnancy (abortifacient, teratogen), and
miscellaneous (alopecia, anaphylaxis, oligosper-
mia, photosensitivity, radiation recall, reactivation
sunburn). Several MTX-induced LPDs have been
reported, including in a patient with SS.48
PDX has a toxicity profile similar to MTX; howev-
er, in thedose ranges commonly used, PDXside ef-
fects tend to bemore common and severe, thereby
limiting its use to more advanced stages of MF/SS
and other aggressive types of CTCLs. The most
common PDX side effects (10%) includemucosi-
tis (17% grade 3), fatigue, nausea, vomiting,
anorexia, skin toxicity, epistaxis, and anemia.16
Toxicity of MTX and PDX can be enhanced
by interactions with other folate antagonists
(dapsone, sulfonamides, trimethoprim), hepato-
toxins (ethanol, retinoids), preexisting liver disease
and other conditions or drugs (eg, nonsteroidal
antiinflammatory drugs, probenecid) that result in
increased blood levels (reduced renal excretion,
displacement from binding proteins).
PEARLS TO HELP MANAGEMENT USING
METHOTREXATE AND PRALATREXATE
It is important to remember that LyP does not need
to be treated if mild. In fact, it is useful to titrate the
dose of MTX close to the point at which a few small
lesions will still occur. In this way, excessively large
doses can be avoided. If oral MTX induces prob-
lematic GI side effects, it can be administered
intramuscularly instead. This also results in ahigher, more prolonged level of MTX in the serum
relative to the same dose given orally. The IM route
may also be useful in those patients who are sus-
pected of poor uptake of MTX from the GI tract
and may be used to enhance compliance when
delivered at a physician’s office. When adminis-
tering IV PDX, the dosing schedule can be modi-
fied by delaying or reducing doses as needed to
help manage severe adverse events such as mu-
cositis. Side effects of both MTX and PDX can
be ameliorated by avoiding concomitant use of
the many other drugs that can potentiate their
toxicity.SUMMARY
This article reviews the use of MTX and its more
recently developed analog, PDX, for the treatment
of cutaneous T-cell LPDs. Although traditionally
regarded principally as proliferation inhibitors that
block the S phase of the cell cycle, folate antago-
nists are now known to inhibit DNA methylation by
depleting cellular stores of S-adenosylmethionine,
the main methyl donor for DNMTs. This has led to
their novel use as agents that can derepress
silenced tumor suppressor genes. Furthermore,
recent mathematical modeling of cancer cell
mutational dynamics provides a rationale for the
use of all anticancer agents as part of combination
therapy regimens rather than as monotherapies. A
strategic advantage of combination regimens is
the ability to attack multiple cell signaling path-
ways simultaneously, thereby preventing the
emergence of drug-resistant tumor clones.
Together, these recent advances hold new prom-
ise for the use of folate antagonists in combination
with other modalities such as IFNs, histone deace-
tylase inhibitors, photodynamic therapy, narrow
band UVB phototherapy, and ionizing radiation
(see Table 1). Clinical validation for this approach
comes from the impressive 74% CR at 1 year
observed among subjects with advanced stage
CTCL who were treated with a combination of
low-dose MTX and IFN-a-2b.34 In aggregate,
these advances are ushering in a new era for the
use of folate antagonists in the management of
cutaneous lymphomas.REFERENCES
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